FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Dextrose 25% Injection
Status: Currently in Shortage
»Date first posted: 02/07/2022
»Therapeutic Categories: Endocrinology/Metabolism; Gastroenterology; Pediatric

Hospira, Inc., a Pfizer Company (Revised 04/27/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
2.5 g/10 mL (250 mg/mL), plastic syringe, 10 per bundle (NDC 0409-1775-10) Limited Supply Available. Next Delivery and Estimated Recovery: June 2022

Pfizer Customer Letter dated March 4, 2022.

Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English